ClinicalTrials.gg

Obesity, Morbid clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 941 studies for Obesity, Morbid across more than 10 countries. 163 are recruiting or about to start. 792 of them are mainly about Obesity, Morbid (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16.

ClinicalTrials.gov finds 1,102 studies for Obesity, Morbid. How that becomes 940 here

This page counts the studies the registry files under Obesity, Morbid, and those it files under no condition that list Obesity, Morbidthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 8, 2026. How condition pages count

  1. 1,102Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −10List Obesity, Morbid as a condition, but the registry did not file them under itMost often written as “Morbid Obesity Requiring Bariatric Surgery” (5), “Clinically Severe Obesity” (4), and “Obesity, Morbid Catheterization, Peripheral” (1). The registry filed them under other conditions only, most often Obesity (7) and Gastroesophageal Reflux (2).
  3. −152Match it another way108 name it in the title, 1 in a keyword, and 43 by a synonym or other text the search reads.
  4. 940The count on this page7 of them list Obesity, Morbid in their own words; the registry filed them under no condition.

Status

Completed
528
Status unknown
138
Recruiting
110
Active, not recruiting
43
Terminated
41
Not yet recruiting
36

Phase

Phase 4
57
Phase 2
31
Phase 3
30
Phase 1
16
Early Phase 1
6

Where

United States
213
Egypt
76
Turkey
70
France
66
Italy
54
Norway
51

Who develops what

Add Obesity, Morbid to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 1 program from 1 company, 1 with this as their studies’ main aim; 1 with a live phase 3 study; 1 primary completion in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 program — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (1)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 18 Jun 2027 est.mibavademab · Regeneron Pharmaceuticals · Phase 3 main aimNCT07220772 A Study Evaluating Mibavademab Treatment of Obesity Due to Leptin (LEP) Gene Mutations in Children, Adolescents and Adults — primary endpoint: Percent change in Body Mass Index (BMI) · 4 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Obesity, Morbid studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here GLP-1 receptor agonists 7 open · Factor Xa inhibitors 1 open · Local anesthetics 8 · Opioids 7 · Stimulants 4

Coming up

49studies finish main data collection within a year1 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 110 Obesity, Morbid studies recruiting now, 21 (19%) set no upper age limit and 84 (76%) stop at 75 or younger. 8 (7%) take children under 18. 5 (5%) are for women only and 2 (2%) for men only; 9 (8%) take healthy volunteers.

Recruiting studies that take each age, of 110
AgeWomenMen
105 (5%)5 (5%)
1898 (89%)96 (87%)
30104 (95%)101 (92%)
40104 (95%)101 (92%)
50103 (94%)102 (93%)
6587 (79%)86 (78%)
7527 (25%)27 (25%)
8523 (21%)22 (20%)

Across all 941 studies, recruiting or not: 71% stop at 75 or younger and 57% at 65; 9% take children; 6% are for women only and 1% for men only; 19% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Obesity, Morbid studies take

Of 28 phase 4 interventional studies under Obesity, Morbid, half reached primary completion within 30 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 430 mo12–43 · 28 studies——
Interventional, no phase25 mo11–48 · 286 studies—25 mo11–48 · 274 studies
Observational46 mo16–132 · 139 studies—46 mo16–132 · 138 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 941. Browse all 941 → or search them.